Mirtazapine for antipsychotic-induced acute akathisia: A systematic review and meta-analysis of randomized placebo-controlled trials

Therapeutic Advances in Psychopharmacology

Volumn 5, Issue 5, 2015, Pages 307-313

  Praharaj, Samir Kumar ^a   Kongasseri, Sreejayan ^a   Behere, Rishikesh V ^a   Sharma, Podila Satya Venkata Narasimha ^a  

^a KASTURBA MEDICAL COLLEGE   (India)

Author keywords

akathisia; meta analysis; mirtazapine; systematic review

Indexed keywords

MIRTAZAPINE; NEUROLEPTIC AGENT; PLACEBO;

AKATHISIA; DRUG RESPONSE; HUMAN; JADAD SCALE; MANTEL HAENSZEL RISK RATIO; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; REMISSION; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA;

EID: 84998183236     PISSN: 20451253     EISSN: 20451261     Source Type: Journal    
DOI: 10.1177/2045125315601343     Document Type: Review

References (38)

1. Ayd F. Jr (1961) A survey of drug-induced extrapyramidal reactions. JAMA 175: 1054–1060.
2. Barnes T. (2003) The Barnes Akathisia Rating Scale – revisited. J Psychopharmacol 17: 365–370.
3. Barnes T. Braude W. (1985) Akathisia variants and tardive dyskinesia. Arch Gen Psychiatry 42: 874–878.
4. Drake R. Ehrlich J. (1985) Suicide attempts associated with akathisia. Am J Psychiatry 142: 499–501.
5. Duncan E. Adler L. Stephanides M. Sanfilipo M. Angrist B. (2000) Akathisia and exacerbation of psychopathology: a preliminary report. Clin Neuropharmacol 23: 169–173.
6. Girishchandra B. Johnson L. Cresp R. Orr K. (2002) Mirtazapine-induced akathisia. Med J Aust 176: 242.
7. Goswami U. Channabasavanna S. (1984) Is akathisia a forerunner of tardive dyskinesia? A clinical report with brief review of literature. Clin Neurol Neurosurg 86: 107–110.
8. Gulsun M. Doruk A. (2008) Mirtazapine-induced akathisia. J Clin Psychopharmacol 28: 467.
9. Hansen L. Kingdom D. (2006) Akathisia as a risk factor for suicide. Br J Psychiatry 188: 192.
10. Higgins J. Thompson S. Deeks J. Altman D. (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557–560.
11. Jadad A. Moore R. Carroll D. Jenkinson C. Reynolds D. Gavaghan D. et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1–12.
12. Juni P. Altman D. Egger M. (2001) Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 323: 42–46.
13. Kumar R. Sachdev P. (2009) Akathisia and second-generation antipsychotic drugs. Curr Opin Psychiatry 22: 293–299.
14. Lima A. Bacalcthuk J. Barnes T. Soares-Weiser K. (2004) Central action beta-blockers versus placebo for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev 4: CD001946.
15. Lima A. Soares-Weiser K. Bacaltchuk J. Barnes T. (2002) Benzodiazepines for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev 1: CD001950.
16. Markoula S. Konitsiotis S. Chatzistefanidis D. Lagos G. Kyritsis A. (2010) Akathisia induced by mirtazapine after 20 years of continuous treatment. Clin Neuropharmacol 33: 50–51.
17. Miller C. Fleischhacker W. (2000) Managing antipsychotic-induced acute and chronic akathisia. Drug Saf 22: 73–81.
18. Miller C. Fleischhacker W. Ehrmann H. Kane J. (1990) Treatment of neuroleptic induced akathisia with the 5-HT2 antagonist ritanserin. Psychopharmacol Bull 26: 373–376.
19. Miller C. Hummer M. Pycha R. Fleischhacker W. (1992) The effect of ritanserin on treatment-resistant neuroleptic induced akathisia: case reports. Prog Neuropsychopharmacol Biol Psychiatry 16: 247–251.
20. Moher D. Liberati A. Tetzlaff J. Altman D. The PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6: e1000097.
21. Newcomer J. Miller L. Faustman W. Wetzel M. Vogler G. Csernansky J. (1994) Correlations between akathisia and residual psychopathology: a by-product of neuroleptic-induced dysphoria. Br J Psychiatry 164: 834–838.
22. Ozyildirim I. Kosecioglu S. (2009) Mirtazapine induced tardive akathisia: a case report. Eur Psychiatry 24: 507.
23. Poyurovsky M. Bergman J. Pashinian A. Weizman A. (2014) Beneficial effect of low-dose mirtazapine in acute aripiprazole-induced akathisia. Int Clin Psychopharmacol 29: 296–298.
24. Poyurovsky M. Epshtein S. Fuchs C. Schneidman M. Weizman R. Weizman A. (2002) Efficacy of low-dose mirtazapine in neuroleptic-induced akathisia: a double-blind randomized placebo-controlled pilot study. Eur Neuropsychopharmacol 12: 300.
25. Poyurovsky M. Epshtein S. Fuchs C. Schneidman M. Weizman R. Weizman A. (2003) Efficacy of low-dose mirtazapine in neuroleptic-induced akathisia: a double-blind randomized placebo-controlled pilot study. J Clin Psychopharmacol 23: 305–308.
26. Poyurovsky M. Pashinian A. Weizman R. Fuchs C. Weizman A. (2006) Low-dose mirtazapine: a new option in the treatment of antipsychotic-induced akathisia. A randomized, double-blind, placebo- and propranolol-controlled trial. Biol Psychiatry 9: 1071–1077.
27. Poyurovsky M. Weizman A. (1997) Serotonergic agents in the treatment of acute neuroleptic-induced akathisia: open-label study of buspirone and mianserin. Int Clin Psychopharmacol 12: 263–268.
28. Poyurovsky M. Weizman A. (2001a) Mirtazapine for neuroleptic-induced akathisia. Am J Psychiatry 158: 819.
29. Poyurovsky M. Weizman A. (2001b) Serotonin-based pharmacotherapy for acute neuroleptic-induced akathisia: a new approach to an old problem. Br J Psychiatry 179: 4–8.
30. Ranjan S. Chandra P. Chaturvedi S. Prabhu S. Gupta A. (2006) Atypical antipsychotic-induced akathisia with depression: therapeutic role of mirtazapine. Ann Pharmacother 40: 771–774.
31. Rathbone J. Soares-Weiser K. (2006) Anticholinergics for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev 4: CD003727.
32. Sachdev P. (1995) The epidemiology of drug-induced akathisia: Part I. Acute akathisia. Schizophr Bull 21: 431–449.
33. Shear M. Frances A. Weiden P. (1983) Suicide associated with akathisia and depot fluphenazine treatment. J Clin Psychopharmacol 3: 235–236.
34. Stryjer R. Grupper D. Strous R. Poyurovsky M. Weizman A. (2004) Mianserin for the rapid improvement of chronic akathisia in a schizophrenia patient. Eur Psychiatry 19: 237–238.
35. Van Putten T. May P. Marder S. (1984) Response to antipsychotic medication: the doctor's and the consumer's view. Am J Psychiatry 141: 16–19.
36. Weiss D. Aizenberg D. Hermesh H. Zemishlany Z. Munitz H. Radwan M. et al. (1995) Cyproheptadine treatment in neuroleptic-induced akathisia. Br J Psychiatry 167: 483–486.
37. Wilson M. 2nd (2005) Mirtazapine for akathisia in bipolar disorder. J Clin Psychopharmacol 25: 394–395.
38. Wirshing W. Van Putten T. Rosenberg J. Marder S. Ames D. Hicks-Gray T. (1992) Fluoxetine, akathisia, and suicidality: is there a causal connection? Arch Gen Psychiatry 49: 580–581.